BioNTech director reports initial 1,927-share holding
BioNTech SE director Ulrich Wandschneider filed an initial statement of beneficial ownership.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioNTech SE director Ulrich Wandschneider filed an initial statement of beneficial ownership. The filing reports indirect beneficial ownership of 1,927 ordinary shares.
The shares are held by beebusy Capital GmbH, where Wandschneider is the sole shareholder and may be deemed to beneficially own the shares. The filing does not report any recent share purchases or sales, only this existing position.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- F1. The ordinary shares are held by beebusy Capital GmbH. The Reporting Person is the sole shareholder of beebusy Capital GmbH and may be deemed to beneficially own the ordinary shares held by beebusy Capital GmbH.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does BioNTech (BNTX) disclose in Ulrich Wandschneider’s Form 3?
Who is beebusy Capital GmbH in relation to BioNTech (BNTX) director Ulrich Wandschneider?
AI-generated analysis. How Rhea-AI works. Not financial advice.